Association of asthma and its genetic predisposition with the risk of severe COVID-19.

To the Editor:

In individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the severity of illness ranges from asymptomatic to fatal. The Centers for Disease Control and Prevention currently list asthma as a risk factor for severe illness from coronavirus disease 2019 (COVID-19). This is a logical determination because the non–COVID-19 literature indicates that patients with asthma have increased susceptibility to viral respiratory infections. In addition, case series of patients with COVID-19 have reported that the asthma prevalence is higher or nondifferent in more severe cases. However, despite the clinical and research importance, no studies have specifically examined the relationship of asthma—let alone of its phenotypes—with incident COVID-19. To address the major knowledge gap, we examined the relationship of asthma and its major phenotypes with the risk of developing severe COVID-19. We also examined the relations of their genetic predisposition with severe COVID-19. The determination of risk factors and potential mechanisms—such as the contribution of genetic predispositions—of severe illness is instrumental for the development of prevention, risk-stratification, and treatment strategies for COVID-19.

We analyzed data from the UK Biobank—a population-based prospective cohort study. The details of study design, setting, participants, data measurements, and data analysis are described in this article’s Online Repository at www.jacionline.org. Briefly, the UK Biobank enrolled approximately 500,000 adults (aged 40-69 years at enrollment) in the period 2006 to 2010. Using standardized protocols, the study has collected comprehensive phenotypic data—for example, demographic characteristics, medical history, physical measures (eg, body mass index), performed genome-wide genotyping, and longitudinally measured health outcomes (eg, hospitalizations) through linkages to national data sets. Starting from March 16, 2020, data of laboratory-confirmed COVID-19 hospitalizations—that is, individuals with severe COVID-19—are available in the UK Biobank.

In the current analysis, we identified all participants with asthma and those without asthma or chronic obstructive pulmonary disease (COPD). To investigate the association of asthma with the risk of severe COVID-19, we constructed unadjusted and adjusted logistic regression models. In the multivariable model, we adjusted for potential confounders (ie, causes of both exposure and outcome of interest), including age, sex, race/ethnicity, and body mass index. On the basis of an a priori hypothesis, we also examined the heterogeneity of effect according to 4 asthma phenotypes, through stratifying the main analysis by coexistence of allergic disease (eczema, food allergy, and/or allergic rhinitis) or of COPD. Next, we used genotyping data to compute a polygenic risk score (PRS) for each asthma group of interest—the sum of all risk alleles weighted by how risky each variant is—representing an individual’s overall genetic risk for asthma (and its phenotypes). Then, we investigated the association of derived asthma PRSs with the risk of severe COVID-19. The details of statistical analysis may be found in this article’s Methods section in the Online Repository at www.jacionline.org. The institutional review board of Harvard University and Massachusetts General Hospital approved the study.

The analytic cohort comprised 492,768 participants in the UK Biobank. Overall, the mean age was 56 ± 8years, 55% were female, and 95% were white. Of these, 65,677 participants (13%) had asthma. Between the participants with asthma and those without asthma, there were no clinically significant differences in most characteristics, except that those with asthma were more likely to be women and have allergic disease and coexistent COPD (Table I ). The UK Biobank also identified a total of 641 patients with severe COVID-19 (see this article’s Methods section). Participants with asthma, compared with those without, had a significantly higher risk of severe COVID-19 (odds ratio [OR], 1.44; 95% CI, 1.18-1.76; P < .001; Fig 1 ). The association remained significant after adjusting for potential confounders (adjusted OR, 1.39; 95% CI, 1.13-1.71; P = .002). These findings were driven by the significant association of nonallergic asthma with severe COVID-19 (adjusted OR, 1.48; 95% CI, 1.15-1.92; P = .003). In contrast, allergic asthma had no statistically significant association with severe COVID-19 (P = .09). In the stratified analysis by coexisting COPD, the significant association persisted in both strata, with a larger magnitude in asthma with COPD (adjusted OR, 1.82; 95% CI, 1.16-2.86; P = .009). In contrast, the PRSs were not significantly associated with the risk of severe COVID-19 across all strata, but the direction of effects was consistently positive (see Table E1 in this article’s Online Repository at www.jacionline.org).

Table I

Baseline characteristics in 492,768 UK Biobank participants

Characteristic	Asthma (n = 65,677; 13%)	No asthma (n = 427,091; 87%)
Demographic
Age (y), mean ± SD	56 ± 8.3	57 ± 8.1
Sex: female	38,006 (57.9)	231,216 (54.1)
Race/ethnicity
White	61,555 (94.3)	401,699 (94.6)
Asian or Asian British	1,388 (2.1)	8,400 (2.0)
Black or black British	1,114 (1.7)	6,904 (1.6)
Mixed	506 (0.8)	2,414 (0.6)
Chinese	153 (0.2)	1,408 (0.3)
Other groups	593 (0.9)	3,922 (0.9)
Total annual household income (£)
≤18,000	14,253 (22.0)	79,252 (18.8)
18,000-30,999	13,482 (20.8)	92,590 (21.9)
31,000-51,999	13,713 (21.2)	95,770 (22.7)
52,000-100,000	10,866 (16.8)	74,809 (17.7)
≥100,000	2,874 (4.4)	19,938 (4.7)
Do not know	3,235 (5.0)	17,396 (4.1)
Prefer not to answer	6,343 (9.8)	42,471 (10.1)
Body mass index (kg/m2), mean ± SD	28.3 ± 5.4	27.3 ± 4.7
Smoking status
Never	35,071 (53.4)	236,600 (55.4)
Previous	23,381 (35.6)	145,057 (34.0)
Current	6,809 (10.4)	42,972 (10.1)
Comorbidities
Allergic diseases
Allergic rhinitis or eczema	28,852 (44.1)	85,354 (20.1)
Food allergy	626 (1.0)	1,570 (0.4)
Cerebrovascular disease	1,190 (1.8)	5,703 (1.3)
COPD	7,836 (11.9)	0 (0)
Coronary artery disease	3,732 (6.0)	16,928 (4.1)
Hypertension	18,937 (30.2)	107,835 (26.4)
Laboratory test at assessment visit, mean ± SD
White blood cells (109 cells/L)	7.17 ± 2.08	6.82 ± 2.01
Neutrophils (109 cells/L)	4.45 ± 1.54	4.18 ± 1.38
Lymphocytes (109 cells/L)	1.97 ± 1.04	1.96 ± 1.12
Monocytes (109 cells/L)	0.47 ± 0.22	0.49 ± 0.22
Eosinophils (109 cells/L)	0.22 ± 0.18	0.17 ± 0.13
Basophils (109 cells/L)	0.04 ± 0.05	0.03 ± 0.05
25-HydroxyvitaminD (nmol/L)	47.2 ± 20.9	48.9 ± 21.1
SARS-CoV-2 PCR test during hospitalization, positive	116 ± 0.2	525 ± 0.1

Data are n (%) of participants unless otherwise indicated.

Fig 1

Associations of asthma and its phenotypes with risks of severe COVID-19 in the UK Biobank. The risk of severe COVID-19 was compared between each of the asthma (overall) and 5 phenotype groups—participants with asthma (n = 65,561), allergic asthma (n = 31,393), nonallergic asthma (n = 34,168), asthma with COPD (n = 7,815), and asthma without COPD (n = 57,746)—to the common reference group (participants without asthma or COPD; n = 426,566). Multivariable logistic regression models adjusted for potential confounders, including patient’s age, sex, race/ethnicity, and body mass index.

Table E1

Multivariable associations between asthma PRSs and risks of severe COVID-19

Asthma groups and PRS models∗	OR (95% CI)	P value
Asthma (overall) PRS†	1.09 (0.97-1.21)	.15
Asthma (overall) PRS‡	1.06 (0.97-1.17)	.21
Allergic asthma PRS‡	1.04 (0.94-1.14)	.45
Nonallergic asthma PRS‡	1.06 (0.97-1.16)	.22
Asthma with COPD PRS‡	1.03 (0.94-1.13)	.51
Asthma without COPD PRS‡	1.06 (0.96-1.16)	.23

ORs and 95% CIs (per 1 Z score of the corresponding PRS) were estimated by logistic regression models adjusting for age, sex, body mass index, genotyping array, and 30 ancestry principal components in the corresponding GWAS.

Asthma (overall) PRS was computed using the TAGC data set.

PRSs for asthma (overall) and 4 asthma phenotypes were computed using the UK Biobank data set.

Consistent with our findings, a case series of adults hospitalized with COVID-19 in 14 US states reported that asthma was one of the most prevalent comorbid conditions (17% prevalence). In contrast, a case series from 2 hospitals in New York (n = 393) reported a similar asthma prevalence between patients with mechanical ventilation use and those without. The largest case series from China (n = 72,314) did not specifically examine asthma as a risk factor for severe COVID-19. Contrary to these case series, the validity of our inferences is buttressed by the use of large population-based prospective cohort study with consideration of different asthma phenotypes and robust analytical approaches.

The mechanisms underlying the asthma-COVID-19 association are beyond the scope of data. Interestingly, however, we found a nonsignificant association between genetic predisposition for asthma and outcome, suggesting a potentially limited discriminatory performance of the PRS used in this study and/or a complex interplay between the pathogen, environment, and host response (eg, differential angiotensin-converting enzyme 2 [ACE2] expression)—beyond the genetics—in the pathobiology of COVID-19. For example, it is possible that asthma, allergic sensitization, and related airway inflammation jointly contribute to the pathobiology of severe COVID-19. Consistent with our findings, a study reported that asthma with high allergic sensitization was associated with low expression of ACE2 (the SARS-CoV-2 receptor) in the nasal epithelia of children, whereas nonallergic asthma was not associated with ACE2 expression. In addition, an analysis of nasal epithelial cells in children with asthma showed that expression of ACE2 and TMPRSS2 (protease that allows efficient virus-receptor binding) is regulated by type 2 inflammation. The current study corroborates these non–COVID-19 data, and extends them by identifying relationships of asthma (and its phenotypes) with severe COVID-19.

The current study has potential limitations. First, misclassification of asthma and its phenotypes is possible, while it is likely unrelated to the outcome. Therefore, this nondifferential misclassification would have biased the inferences toward the null. Second, as with any observational study, causal inference may be confounded by unmeasured factors (eg, access to health care). Yet, the study focused on severe COVID-19 requiring inpatient management, thereby mitigating this problem. Finally, the study consisted mainly of white individuals and focused on severe COVID-19, and we must cautiously generalize the inferences to other populations or individuals with mild to moderate COVID-19. Regardless, our data are highly relevant for hundreds of thousands of patients hospitalized for COVID-19.

In conclusion, the large population-based cohort study demonstrated that adults with asthma had a higher risk of severe COVID-19, which was driven by the increased risk in patients with nonallergic asthma. In contrast, the risk of severe COVID-19 was not significantly elevated in patients with allergic asthma. In addition, the study demonstrated the absence of association between the existing genetic polygenic score for asthma and COVID-19. These observations should help clinicians optimize risk-stratification of patients with asthma (and its phenotypes). Furthermore, our inferences should advance the research into delineating the complex interrelations between SARS-CoV-2 infection, airway inflammation, and outcomes in patients with asthma.

Table E2

Discriminatory performance (area under the receiver-operating characteristic curve) of PRS, according to different models

Asthma groups	PRS model with different priors on fraction causal markers
	0.001	0.003	0.01	0.03	0.1	0.3	1.0
Asthma (overall) PRS∗	0.510	0.517	0.582	0.576	0.569	0.566	0.564
Asthma (overall) PRS†	0.516	0.535	0.570	0.626	0.612	0.603	0.599
Allergic asthma PRS†	0.597	0.558	0.600	0.605	0.596	0.590	0.586
Nonallergic asthma PRS†	0.554	0.561	0.566	0.563	0.559	0.557	0.556
Asthma with COPD PRS†	0.549	0.561	0.565	0.564	0.564	0.564	0.564
Asthma without COPD PRS†	0.597	0.531	0.571	0.603	0.593	0.586	0.583

Results in boldface are the highest area under receiver-operating characteristic curve value to discriminate the corresponding asthma group among the 7 models for each asthma group.

Asthma (overall) PRS was computed using the TAGC data set.

PRSs for asthma (overall) and 4 asthma phenotypes were computed using the UK Biobank data set.